Last reviewed · How we verify
NVGH Vi-CRM197 — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
NVGH Vi-CRM197 (NVGH Vi-CRM197) — Novartis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NVGH Vi-CRM197 TARGET | NVGH Vi-CRM197 | Novartis | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NVGH Vi-CRM197 CI watch — RSS
- NVGH Vi-CRM197 CI watch — Atom
- NVGH Vi-CRM197 CI watch — JSON
- NVGH Vi-CRM197 alone — RSS
Cite this brief
Drug Landscape (2026). NVGH Vi-CRM197 — Competitive Intelligence Brief. https://druglandscape.com/ci/nvgh-vi-crm197. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab